EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel By Ogkologos - August 26, 2025 363 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults from 26 years of age with relapsed or refractory B cell precursor ALL Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Daughter And Her Terminally Ill Dad Go On Bucket List Adventures... January 24, 2022 2021 ASCO Annual Meeting: New Treatments and Research Advances in Esophageal... June 3, 2021 One Family’s Mission to Stop Hair Loss from Chemotherapy: Your Stories... July 16, 2020 Why is Colorectal Cancer Rising Rapidly among Young Adults? November 5, 2020 Load more HOT NEWS Why Wearing Comfortable Clothes During Cancer Treatment Matters Droplet Transmission vs. Airborne… What’s the difference? Young Women with Breast Cancer Often Forgo Hormone Therapy Due to... Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically...
